Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir

References

• Ali J, Fazil M, Qumbar M, et al. (2014). Colloidal drug delivery system: amplify the ocular delivery. Drug Deliv 3:1–17
   Web of Science ®Google Scholar
• Baba K, Tanaka Y, Kubota A, et al. (2011). A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolyzable dye. J Control Release 153:278–87
   PubMed Web of Science ®Google Scholar
• Baeyens V, Gurny R. (1997). Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv 72:191–202
   PubMedGoogle Scholar
• Diebold Y, Calonge M. (2010). Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596–609
   PubMed Web of Science ®Google Scholar
• Duvvuri S, Janoria KG, Mitra AK. (2005). Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J Control Release 108:282–93
   PubMed Web of Science ®Google Scholar
• El-Samaligy M, Rojanasakul Y, Charlton JF, et al. (1996). Ocular disposition of nanoencapsulated acyclovir and ganciclovir via intravitreal injection in rabbit's eye. Drug Deliv 2:93–7
   Google Scholar
• Gupta H, Aqil M, Khar RK, et al. (2013). Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention. Drug Deliv 20:306–9
   PubMed Web of Science ®Google Scholar
• Kansara V, Hao Y, Mitra AK. (2007). Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina. J Ocul Pharmacol Ther 23:321–34
   PubMed Web of Science ®Google Scholar
• Kennedy DP, Clement C, Arceneaux RL, et al. (2011). Ocular herpes simplex virus type 1: is the cornea a reservoir for viral latency or a fast pit stop? Cornea 30:251–9
   PubMed Web of Science ®Google Scholar
• Lee LY, Wang CH, Smith KA. (2007). Micro-porous paclitaxel-loaded PLGA foams – a new implant material for controlled release of chemotapeutic agents. Cambridge, MA: Massachusetts Institute of Technology
   Google Scholar
• Liesegang TJ. (1988). Ocular herpes simplex infection: pathogenesis and current therapy. Mayo Clin Proc 63:1092–105
   PubMed Web of Science ®Google Scholar
• Lopez-Gasco P, Iglesias I, Benedi J, et al. (2011). Paclitaxel-loaded polyester nanoparticles prepared by spray-drying technology: in vitro bioactivity evaluation. J Microencapsul 28:417–29
   PubMed Web of Science ®Google Scholar
• Majumdar S, Macha S, Nashed Y, et al. (2004). Expression of peptide transporters on rabbit retina: a strategy to improve retinal delivery of ganciclovir. Lett Drug Des Discov 1:73–7
   Google Scholar
• Majumdar S, Nashed YE, Patel K, et al. (2005). Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocul Pharmacol Ther 21:463–74
   PubMed Web of Science ®Google Scholar
• Majumdar S, Tirucherai GS, Pal D, et al. (2003). Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea. AAPS PharmSci 5:72–85
   Google Scholar
• Matthews T, Boehme R. (1988). Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10:S490–4
   PubMedGoogle Scholar
• Mu L, Feng SS. (2003). A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 86:33–48
   PubMed Web of Science ®Google Scholar
• Ohara PT, Chin MS, LaVail JH. (2000). The spread of herpes simplex virus type 1 from trigeminal neurons to the murine cornea: an immunoelectron microscopy study. J Virol 74:4776–86
   PubMed Web of Science ®Google Scholar
• Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110–11
   PubMedGoogle Scholar
• Perng GC, Jones C. (2010). Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. Interdiscip Perspect Infect Dis, 2010:1–18. Article ID 262415
   Google Scholar
• Plourde R, Merwin J, Ernst MF, et al. (1995). Acyclovir–glycoprotein conjugates are potent inhibitors of hepatitis B virus replication. Drug Deliv 2:136–43
   Google Scholar
• Ramyadevi D, Sandhya P. (2014). Dual sustained release delivery system for multiple route therapy of an antiviral drug. Drug Deliv 21:276–92
   PubMed Web of Science ®Google Scholar
• Sood N, Bhardwaj A, Mehta S, et al. (2014). Stimuli-responsive hydrogels in drug delivery and tissue engineering. Drug Deliv 21:1–23
   PubMed Web of Science ®Google Scholar
• Suresh PS, Tullo AB. (1999). Herpes simplex keratitis. Indian J Ophthalmol 47:155–65
   PubMedGoogle Scholar
• Wilhelmus KR. (2000). The treatment of herpes simplex virus epithelial keratitis. Trans Am Ophthalmol Soc 98:505–32
   PubMedGoogle Scholar
• Xu F, Sternberg MR, Kottiri BJ, et al. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964–73
   PubMed Web of Science ®Google Scholar
• Zhao C, Yuan G, Han CC. (2012). Stabilization, aggregation, and gelation of microsphere induced by thermosensitive microgel. Macromolecules 45:9468–74
   Web of Science ®Google Scholar